文献速递心血管PET

锝99m焦磷酸盐显像诊断转甲状腺素蛋白心脏淀粉样变性:一项不断演变的检查

Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-11-18

该研究在四级医疗中心分析2010至2019年注射后1小时行锝99m焦磷酸盐扫描的患者,扫描量在2019年达峰值132例(P<0.001),753例中视觉评分0分307例(41%)、1分177例(23%)、2或3分269例(36%),心脏与对侧胸部比值≥1.5者249/751例(33%);196例确诊转甲状腺素蛋白心脏淀粉样变性中143例(73%)接受了基因检测,103例心肌活检中2级和3级扫描诊断敏感度94%、特异度89%,3级扫描特异度100%;以SPECT为参考标准,平面显像在2级扫描中假阳性16/25例(64%)。

要点

  • 2级和3级锝99m焦磷酸盐扫描对转甲状腺素蛋白心脏淀粉样变性敏感度94%、特异度89%,3级扫描特异度100%。
  • 以SPECT为参考标准,平面显像在2级扫描中假阳性16/25例(64%),需加做SPECT区分心肌摄取与血池。
  • 单克隆蛋白检测和基因检测是排除轻链淀粉样变性和确认转甲状腺素蛋白突变的关键环节。

核心结论

  • 锝99m焦磷酸盐扫描用于转甲状腺素蛋白心脏淀粉样变性评估的使用正在增加,纳入单克隆蛋白检测和SPECT显像对于排除轻链淀粉样变性及区分心肌摄取与血池至关重要。

研究设计与样本

  • 研究分析了2010至2019年在一家四级医疗中心注射后1小时行锝99m焦磷酸盐扫描的患者,并提取临床信息、分析SPECT结果。
  • 共纳入753例患者(516例男性,平均年龄77岁),其中751例有可分析的心脏与对侧胸部比值。

关键影像表现/征象

  • 753例中视觉评分0分307例(41%)、1分177例(23%)、2或3分269例(36%)。
  • 751例有可分析心脏与对侧胸部比值的患者中,249例(33%)比值≥1.5。
  • 以SPECT为参考标准,平面显像在25例2级扫描中假阳性16例(64%)。

诊断标准与关键数值

  • 在103例接受心肌活检的患者中,2级和3级锝99m焦磷酸盐扫描诊断转甲状腺素蛋白心脏淀粉样变性的敏感度为94%、特异度为89%,3级扫描特异度为100%。
  • 550例患者评估了单克隆蛋白检测状态,其中174例(32%)未同时进行血清免疫固定电泳和血清游离轻链分析,331例(60%)未完成全部3项检测(血清免疫固定电泳、血清游离轻链分析和尿蛋白电泳)。
  • 196例确诊转甲状腺素蛋白心脏淀粉样变性患者中,143例(73%)接受了转甲状腺素蛋白突变基因检测。

临床应用与阅片要点

  • 锝99m焦磷酸盐扫描使用增加,2019年扫描量达峰值132例(P<0.001),而心内膜心肌活检率保持稳定。
  • 采用锝99m焦磷酸盐扫描无创评估转甲状腺素蛋白心脏淀粉样变性时,应包含单克隆蛋白检测和SPECT显像,以排除轻链淀粉样变性并区分心肌摄取与血池。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to characterize trends in technetium Tc 99m pyrophosphate (99mTc-PYP) scanning for amyloid transthyretin cardiac amyloidosis (ATTR-CA) diagnosis, to determine whether patients underwent appropriate assessment with monoclonal protein and genetic testing, to evaluate use of single-photon emission computed tomography (SPECT) in addition to planar imaging, and to identify predictive factors for ATTR-CA.

BACKGROUND: 99mTc-PYP scintigraphy has been repurposed for noninvasive diagnosis of ATTR-CA. Increasing use of 99mTc-PYP can facilitate identification of ATTR-CA, but appropriate use is critical for accurate diagnosis in an era of high-cost targeted therapeutics.

METHODS: Patients undergoing 99mTc-PYP scanning 1 h after injection at a quaternary care center from 2010 to 2019 were analyzed; clinical information was abstracted; and SPECT results were analyzed.

RESULTS: Over the decade, endomyocardial biopsy rates remained stable with scanning rates peaking at 132 in 2019 (p < 0.001). Among 753 patients (516 men, mean age 77 years), 307 (41%) had a visual score of 0, 177 (23%) of 1, and 269 (36%) of 2 or 3. Of 751 patients with analyzable heart to contralateral chest ratios, 249 (33%) had a ratio ≥1.5. Monoclonal protein testing status was assessed in 550 patients, of these, 174 (32%) did not undergo both serum immunofixation and serum free light chain analysis tests, and 331 (60%) did not undergo all 3 tests-serum immunofixation, serum free light chain analysis, and urine protein electrophoresis. Of 196 patients with confirmed ATTR-CA, 143 (73%) had genetic testing for transthyretin mutations. In 103 patients undergoing cardiac biopsy, grades 2 and 3 99mTc-PYP had sensitivity of 94% and specificity of 89% for ATTR-CA with 100% specificity for grade 3 scans. With respect to SPECT as a reference standard, planar imaging had false positive results in 16 of 25 (64%) grade 2 scans.

CONCLUSIONS: Use of noninvasive testing with 99mTc-PYP scanning for evaluation of ATTR-CA is increasing, and the inclusion of monoclonal protein testing and SPECT imaging is crucial to rule out amyloid light chain amyloidosis and distinguish myocardial retention from blood pooling.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Poterucha TJ, Elias P, Bokhari S, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2020. PMID: 33221204. doi:10.1016/j.jcmg.2020.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。